Announcement

Collapse
No announcement yet.

Autologous Stem Cell Transplant in Adult Multiple Sclerosis Patients: A Study from No

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Autologous Stem Cell Transplant in Adult Multiple Sclerosis Patients: A Study from No

    ORIGINAL ARTICLE
    Year : 2020 | Volume : 68 | Issue : 2 | Page : 454-457

    Autologous Stem Cell Transplant in Adult Multiple Sclerosis Patients: A Study from North India

    Aniruddha Dayama, Rahul Bhargava, Santosh R Kurmi, Sachin Jain, Vikas Dua
    Department of Hematology and BMT, Fortis Memorial Research Institute, Gurgaon, Haryana, India

    Date of Web Publication 15-May-2020

    Abstract

    Introduction: Autologous Stem Cell Transplant (ASCT) provides long periods of progression-free-survival in multiple sclerosis (MS). This is an observational study to demonstrate the safety of ASCT in MS patients at a transplant center in North India using a lymphoablative regimen.

    Materials and Methods: MS patients > 18 years referred by a neurologist or who came of their own volition were evaluated. Kurtzke Expanded Disability Status Scale (EDSS) score was calculated and those with a score of >7 were excluded. Informed written consent was taken. Mobilization was done with G-CSF with prednisolone to prevent disease flare-up. A minimum of 2 106 CD34 cells/kg was collected. Conditioning regimen consisted of rabbit ATG and cyclophosphamide. Rituximab 375 mg/m2 was given to prevent EBV reactivation and disease relapse. Antibiotic prophylaxis was given with levofloxacin, fluconazole, and valacyclovir. Any persistent change in EDSS scores ≥0.5 was considered significant.

    Results: Twenty patients were included. Seven patients had positive urine cultures prior to transplant and were treated before starting any chemotherapy. Majority patients were women (13/20). All patients developed febrile neutropenia, which was managed as per department policy. There was no mortality. Subjective symptoms improved in all patients. EDSS score improved in 6/19 patients (5/6 with RRMS) with no disease progression in any patient at a median follow-up duration of 242 days.

    Conclusion: ASCT can be done safely for patients with relatively high EDSS scores with additional precautions for screening for infections. RRMS patients with the active disease show most improvement. SPMS patients may not show significant improvement in the short term.

    FULL STUDY (FREE):
    http://www.neurologyindia.com/articl...;aulast=Dayama
    Dave Bexfield
    ActiveMSers
Working...
X